Check out the full press release here.
In the primate study, all the animals provided the vaccine and exposed to COVID-19 6 weeks later were immune except for one, which had just low levels of the virus..
J&J stated its wanting to begin the last phase of testing in September in a trial of over 1,000 individuals. Its increase production to attempt to supply over 1 billion doses to individuals worldwide, the drugmaker said, but did not say just how much it will charge for the vaccine..
The company launched human trials in Belgium and the U.S. after an early trial showed its vaccine helped protect a group of primates from COVID-19 infection after a single dosage.
J&Js capability to produce an immune action in a single dose may offer it an advantage over other drugmakers rolling out vaccines that took two dosages to elicit an immune response.
Maia Anderson –
Thursday, July 30th, 2020
J&J said July 30 that it has started its very first human trials of its speculative COVID-19 vaccine..
More posts on pharmacy: Moderna proposes coronavirus vaccine will cost $50 to $60 per courseUS sending out Texas hospitals 500 cases of remdesivir as COVID-19 cases surgeOperation Warp Speed: a timeline up until now.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.